Why the study?
What are the mechanisms and management strategies for cardiovascular adverse effects associated with targeted antiangiogenic drugs?
What are the mechanisms and management strategies for cardiovascular adverse effects associated with targeted antiangiogenic drugs?
Understanding the unique cardiovascular adverse effects of targeted antiangiogenic drugs is crucial for maximizing clinical benefits and minimizing detrimental effects in cancer patients.
May warrant CV monitoring with anti-VEGF therapy; leaves optimal management strategies open for prospective trials.
Anticancer treatment has evolved enormously over the last decade. Drugs targeting receptor tyrosine kinases, VEGFR and EGFR have changed the treatment landscape of certain cancers and have shifted the theme of anticancer therapy toward personalized care. However, these newer agents also come with unique side-effect profiles not seen with conventional chemotherapy including serious cardiovascular adverse effects. Hence, meticulous understanding of the adverse effects is crucial in maximizing clinical benefits and minimizing detrimental effects of these newer drugs. We have reviewed the cardiovascular adverse effects of anti-VEGF therapy in this article.
No takes yet. Share an insight, caveat, or question.
Sundararajan et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: